Our Expert Network

1. Why RNA–LNP Development Needs Higher-Resolution Analytics In 2027 9/11/2026

   Raising analytical resolution is among the cheapest interventions available. With regulators tightening and capital selective, it is also among the most consequential.

2. Beyond GalNAc: Reengineering siRNA For Extrahepatic Delivery 9/9/2026

   We discuss why effective extrahepatic delivery remains one of the field's biggest obstacles and how chemical engineering may provide a new path forward.

3. Engineering CAR T Cells With mRNA-LNPs: Applying Oncology Learnings To Allergic Diseases 9/4/2026

   Targeted lipid nanoparticles (LNPs) could deliver mRNA encoding a CAR directly to T cells inside a patient with allergic disease. The potential implications extend beyond a single allergic condition. 

4. RNA Oligonucleotide Synthesis: How Advanced Manufacturing Technologies Are Accelerating Innovation 9/3/2026

   From a tech perspective, the manufacturing objective is shifting toward integrated process optimization. Automated reaction control, multivariate analytics, and more can connect molecular quality with operational performance. 

5. AI Agents Are Only As Good As The RNA Knowledge Behind Them 9/3/2026

   The RNA field is producing extraordinary volumes of information. Yet, giving an AI system access to more information does not necessarily make the system more scientifically intelligent.

6. Will 2027 See A Meteoric Rise Of Programmable Nanomedicine? 9/2/2026

   The significance of programmable nanomedicines is not simply that nanoparticles can carry more functions. It is that biological information can become part of the control logic.

7. From Cell State Reprogramming To The Clinic: Turning The Regulatory Genome Into RNA Medicines (Pt. 2) 8/26/2026

   Ounzain discusses how regulatory genome biology is being translated into drug discovery, from identifying lncRNA targets to building clinically relevant therapeutics and more.

8. Why Delivery Is Defining The Next Era Of Neuromuscular Therapeutics 8/19/2026

   Emerging therapies are being designed to safely deliver oligonucleotides to disease-relevant tissues. Delivery is no longer a technical hurdle to overcome but a strategic lever.

9. Drugging The tRNA Control System 8/19/2026

   Drug discovery has usually treated transfer RNA as cellular infrastructure: indispensable, highly conserved, and therefore dangerous to perturb. That description is accurate but incomplete. 

10. Analytical Platforms: The Foundation Of The Next Generation Of RNA Therapeutics 8/11/2026

    RNA therapeutics are entering a new era where analytical platforms drive scalability, regulatory confidence, manufacturing flexibility, and the development of increasingly complex products.